Transgene Sa · EURONEXT:TNG
Transgene Sa — Investor Presentation (January 2024)
26 slides from Transgene Sa's investor presentation, Jan 8, 2024
Slide 1: Unlocking the Full Potential of the Immune System Against Cancer
Unlocking the Full Potential of the Immune System Against Cancer Corporate Presentation January 8, 2024
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be
Slide 3: Transgene: Innovative Clinical-Stage Immunotherapy Portfolio Based on Viral Vectors
Transgene Innovative Clinical-Stage Click to edit Master title style Immunotherapy Portfolio Based on Viral Vectors Cutting-edge Additional individualized neoantigen immuno-oncology programs cancer vaccine (TG4050) with clinical proof of principle Significant • Proof of principle in randomized • Sha
Slide 4: TG4050 – A Novel Individualized Cancer Immunotherapy
TG4050 – A Novel Individualized Cancer Immunotherapy Click to edit Master title style MVA VECTOR BENEFITS THE RIGHT NEOANTIGENS INDICATION Induces broad and specific immune Comprises up to 30 neoantigens Targeting head and neck patients – response – 100% patients treated selected using NEC’s artific
Slide 5: Focus on Neoantigen Cancer Vaccine While Delivering Proof of Principles
Focus on Neoantigen Cancer Vaccine While Click to editDelivering Master title styleProof of Principles on a Diversified Immunotherapy Portfolio Product Indication Collaboration Discovery Phase I Phase II Key upcoming catalysts INDIVIDUALIZED NEOANTIGEN CANCER VACCINES Head and neck Additional immuno
Slide 6: Cancer Therapeutic Vaccines
Cancer Therapeutic Vaccines Focused on delivering the promise of individualized cancer vaccine
Slide 7: myvac® - TG4050 | Combines Unique Know How and Expertise
myvac® - TG4050 | Combines Unique Know How and Expertise Click to edit Master title style MVA viral vector: a powerful Artificial Intelligence to identify platform for vaccine development up to 30 potent neoantigens Strongly immunogenic vector o NEC’s machine learning environment based on o Demonstr
Slide 8: TG4050 | HPV-Negative Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy
TG4050 | HPV-Negative Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy Click to edit Master title style Need to prevent or delay relapse TG4050 (single agent) Clinical situation where checkpoint blockers have failed Repeated injections (ie. KN412, Javelin 100) 24-month PFS remains app
Slide 9: TG4050 | Generates an Unprecedented Rate of T Cell Response Against Tumor
TG4050 | Generates an Unprecedented Rate of T Cell Response Against Tumor Click to edit Master Specific Epitopes title style Number of positive responses per patients Head and neck cancer trial de novo responses Amplified responses Stable responses* Induction of multiple T cell responses in all trea
Slide 10: Profound Remodelling of Immune Cells Consistent with Anti Tumor Response
Profound Remodelling of Immune Cells Consistent with Anti Tumor Response Suggests that the Click to edit Master Vaccine Effectively Primes the Immune System title style neg aiveNaive in CD4 in CD4 Naive in CD8b Naive % CD16 in in CD56dim CD8b Memory in CD4 NKMemory in CD4 Memory in CD8b Effector in
Slide 11: Promising First Signals of Clinical Activity in Adjuvant Setting
Promising First Signals of Clinical Activity in Adjuvant Setting Click to edit Master title style Head & Neck Cancer Trial No related SAEs 32 patients randomized – May 2023 Good safety profile 6 months 12 months 18 months 24 months 30 months Arm A: TG4050 All 16 treated patients were disease-free si
Slide 12: TG4050 | Building upon Proof of Concept with a Randomized Phase II Trial
TG4050 | Building upon Proof of Concept with a Randomized Phase II Trial Mid-term objective: Click to edit Master title style Establish TG4050 as the SOC in adjuvant setting for patients with H&N cancers one patient • one genome • one vaccine Excellent Signs Intend to launch randomized Phase II tria
Slide 13: TG4001 | Proof of Concept Data Expected in H2 2024 – Seeking Partnership in 2024
TG4001 | Proof of Concept Data Expected in H2 2024 – Seeking Partnership in 2024 Click to edit Master title style Ongoing Phase II trial in patients with HPV16-positive anogenital cancer Ongoing trial to readout in H2 2024 incl. cervical, vulvar, vaginal, penile and anal cancers NCT: 03260023 • To d
Slide 14: Oncolytic Viruses
Oncolytic Viruses Rapidly Generating Multiple Virus-Powered Off-the-Shelf Drug Candidates Targeting Solid Tumors
Slide 15: Our Oncolytic Viruses (OV) – Combined Effects of Vector, Payload and Immune Stimulation
Our Oncolytic Viruses (OV) – Combined Effects of Vector, Payload and Immune Stimulation Compelling Clinical Click to edit Master Data Support Intravenous (IV) Route of Administration title style Cancer cell death through multiple MOAs Patented Backbone VVcopTK-RR- vector with multiple competitive ad
Slide 16: TG6050 administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor
TG6050 administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor Ongoing Click to edit Phase I Trial Master title style to Assess Systemic Route of Administration Oncolytic armed with IL-12 and anti-CTLA4 Ab • Triggers a powerful antitumor immune response • Restores the immune defenses w
Slide 17: BT-001 | OV Armed with Anti-CTLA4 Ab + GM-CSF
BT-001 | OV Armed with Anti-CTLA4 Ab + GM-CSF 50/50 collaboration with BioInvent Ongoing Click to edit Phase I Trial Master title style Assessing IT* Route of Administration The right virus + payload Positive Phase I part A VVcopTK-RR- oncolytic armed with readout BioInvent’s potent anti-CTLA4 Ab +
Slide 18: Outlook
Outlook transgene
Slide 19: Company Funded to Deliver Multiple Value Generating Milestones
Company Funded to Deliver Multiple Value Generating Milestones Ownership As of September 30, 2023 FINANCIAL VISIBILITY until end of 2024 60% Free float 40% • Listed on Euronext Paris • ISIN: FR0005175080 - Ticker: TNG 19
Slide 20: 2024 Value Creating News Flow Expected in Next Months
2024 Value Creating News Flow Expected in Next 12 Months Click to edit Master title style TG4050 Ongoing randomized Phase II Phase I Proof of principle already obtained in head and • Additional immunogenicity and clinical follow up • Initiation of the trial in neck cancer (adjuvant) data (H1 2024) c
Slide 21: Investment Highlights
Investment Highlights Click to edit Master title style Lead program TG4050 Additional programs and R&I Unique and highly potent to deliver data in 2024 activity to deliver news flow and viral vector based and create significant value fuel Transgene’s portfolio in the immunotherapies by 2026 mid term
Slide 22: Appendices
Ccpameerane Appendices
Slide 23: New Leadership to Take Transgene to the Next Level
New Leadership to Take Transgene to the Next Level Click to edit Master title style ÉRIC QUÉMÉNEUR, MAUD BRANDELY, MD, ALESSANDRO RIVA, MD Chairman & CEO PharmD, PhD - Executive PhD - VP, Medical Affairs VP - Chief Scientific Officer - Chief Medical Officer 30+ years experience CHRISTOPHE ANCEL, ARN
Slide 24: Viral Vaccines Prime Both Long Lasting Innate and Adaptive Immunity
Viral Vaccines Prime Both Long Lasting Innate and Adaptive Immunity Click to edit Master title style Post-exposure time Few hours – few days (<48h) Few days Few Weeks Few Months Granulocytes Dendritic cells CD8+ T cells Macrophages CD4+ T cells B cells Plasma cells Antibodies Innate immunity NK cell
Slide 25: TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities
TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities Combines Bioengineering Click to edit Master title style and Digital Transformation STANDARD DATA PROCESSING, ROUTINE GENE/EXOME ARTIFICIAL GMP TREATMENT TUMOR BIOPSY SEQUENCING INTELLIGENCE GENE EDITING MANUFACTURING ADMINIS
Slide 26: Contact
C O N TA C T Lucie Larguier VP, Investor Relations and Corporate Communication +33 6 7624 7227 larguier@transgene.fr 400 Boulevard Gonthier d’Andernach | Parc d’Innovation | CS80166 67405 Illkirch Graffenstaden Cedex | France Tél.: + 33 (0)3 88 27 91 21 | www.transgene.fr